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M A J O R A R T I C L E
Excessive Cytolytic Responses Predict Tuberculosis Relapse
After Apparently Successful Treatment
Jacqueline M. Cliff,1 Jang-Eun Cho,1,a Ji-Sook Lee,1 Katharina Ronacher,2,3 Elizabeth C. King,1 Paul van Helden,2,3 Gerhard Walzl,2,3 and Hazel M. Dockrell1
1TB Centre and Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom; 2Division of Molecular Biology
and Human Genetics, Department of Biomedical Sciences/MRC Centre for Molecular and Cellular Biology/DST, and 3NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences,
Stellenbosch University, Cape Town, South Africa
Background. Currently, there are no tools to accurately predict tuberculosis relapse. This study aimed to determine whether patients
who experience tuberculosis relapse have different immune responses to mycobacteria in vitro than patients who remain cured for 2 years.
Methods. Patients with an initial episode of pulmonary tuberculosis were recruited in South Africa. Diluted blood, collected at diag-
nosis and after 2 and 4 weeks of treatment, was cultured with live Mycobacterium tuberculosis for 6 days, and cellular RNA was frozen.
Gene expression in samples from 10 patients who subsequently experienced relapse, conﬁrmed by strain genotyping, was compared to
that in samples from patients who remained cured, using microarrays.
Results. At diagnosis, expression of 668 genes was signiﬁcantly different in samples from patients who experienced relapse, compared
with expression in patients who remained successfully cured; these differences persisted for at least 4 weeks. Gene ontology and biological
pathways analyses revealed signiﬁcant upregulation of genes involved in cytotoxic cell-mediated killing. Results were conﬁrmed by real-
time quantitative reverse-transcription polymerase chain reaction analysis in a wider patient cohort.
Conclusions. These data show that patients who will subsequently experience relapse exhibit altered immune responses, including
excessively robust cytolytic responses toM. tuberculosis in vitro, at the time of diagnosis, compared with patients who will achieve durable
cure. Together with microbiological and clinical indices, these differences could be exploited in drug development.
Keywords. transcriptomics; microarray; drug development; blood; patient.
Following antimycobacterial drug treatment, the majority of
treatment-adherent patients with tuberculosis due to drug-sus-
ceptibleMycobacterium tuberculosis remain healthy and disease
free. However, approximately 5% of patients experience recur-
rent tuberculosis within 2 years of treatment completion [1].
Tuberculosis recurrence can be due to either reinfection with
a new organism or relapse with the sameM. tuberculosis isolate;
it is unknown why mycobacteria persist in some individuals
after 6 months of treatment. In Cape Town, South Africa, a set-
ting with a high tuberculosis burden, tuberculosis relapse pre-
dominates in the ﬁrst year after tuberculosis treatment
completion, whereas reinfection is more common later [2].
New tuberculosis drugs or regimens are needed, but there are
no easy ways to determine the efﬁcacy of compounds under
development. The 2-year relapse rate is used to measure drug
efﬁcacy in trials of tuberculosis drugs or regimens, but demon-
stration of reduced relapse/enhanced efﬁcacy will require many
thousands of patients and is very time-consuming and costly.
Biomarkers that predict the response to tuberculosis treatment
and the risk of tuberculosis relapse early in clinical trials would
greatly help to evaluate candidate drugs and select those for fur-
ther development [3].
Tuberculosis recurrence is associated with the bacterial bur-
den at the time of diagnosis and with delayed sputum conver-
sion [4]. Early Bactericidal Assays performed during the ﬁrst
two weeks of treatment, and sputum conversion rates after 2
months of treatment, can indicate early drug efﬁcacy but cannot
measure the killing of persistent bacterial subpopulations later
in treatment. Because bacteria with the capability of persisting
and causing tuberculosis relapse cannot be detected by current
techniques, identiﬁcation of patients at risk of tuberculosis re-
lapse following treatment would revolutionize clinical trials of
new treatments and facilitate clinical management.
Gene expression proﬁling of ex vivo whole-blood specimens
has revealed transcriptomic changes in patients with tuberculo-
sis, compared with healthy people [5–7], and large-scale chang-
es in gene expression during successful tuberculosis drug
treatment [8–10]. A cross-sectional study of patients who previ-
ously experienced tuberculosis recurrence identiﬁed genes that
discriminated this group from patients who remained cured
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after 1 tuberculosis episode [11]. Array technology has been
used to investigate human phagocyte responses to pathogens,
including M. tuberculosis, Toxoplasma gondii, and Leishmania
species, [12, 13] and CD4+ and CD8+ T-cell responses to
M. tuberculosis in vitro [14]. However, only whole-blood cul-
tures contain all circulating leukocytes, including neutrophils,
which play an important role in tuberculosis immunity and im-
munopathology [5, 15]. Variations in mycobacterial antigen–
induced cytokine production [16, 17] or mycobacterial growth
inhibition [18] among study populations are readily detectable
in cultures of diluted whole-blood specimens, which tradition-
ally include culture periods of approximately 6 days.
We hypothesized that cultures of diluted whole-blood speci-
mens and microarray technology would enable identiﬁcation of
differences early during tuberculosis treatment in patients who
subsequently experienced relapse, compared with patients who
remained disease free for 2 years. Such differences could be de-
veloped into biomarkers to predict tuberculosis drug efﬁcacy
and could reveal why some people are more susceptible to
tuberculosis relapse.
METHODS
Study Design and Sample Collection
Fourteen healthy BCG-vaccinated donors were recruited at the
London School of Hygiene and Tropical Medicine. In Cape
Town, 263 non–human immunodeﬁciency virus (HIV)-infected,
smear-positive, untreated patients experiencing their ﬁrst epi-
sode of pulmonary tuberculosis were recruited as part of a larger
prospective cohort study [4]. Patients received conventional
therapy (ie, isoniazid, rifampicin, pyrazinamide, and ethambu-
tol for 2 months, followed by isoniazid and rifampicin for 4
months) recommended by the South African National Tuber-
culosis Program, and venous blood samples were collected at in-
tervals throughout treatment. All patients were categorized as
having achieved cure or completed treatment at the end of
the ﬁrst-episode treatment. Patients with a second tuberculosis
episode within 2 years of follow-up were categorized as having
tuberculosis relapse orM. tuberculosis reinfection, using restric-
tion fragment–length polymorphism genotyping. Treatment
adherence was monitored, and patients infected with drug-
resistant strains were excluded. Patients gave written informed
consent, with ethical approval for the study granted by the eth-
ics committees of Stellenbosch University (Faculty of Health
Sciences), the London School of Hygiene and Tropical Medi-
cine, and the director of health of the City of Cape Town.
In Vitro Stimulation With Live Mycobacteria
One milliliter of blood, diluted 10-fold in HEPES-buffered Ros-
well Park Memorial Institute 1640 medium (Sigma-Aldrich,
Missouri) supplemented with L-glutamine (Sigma-Aldrich),
was cultured with 4 × 105 colony-forming units of M. tubercu-
losis H37Rv or Mycobacterium bovis bacillus Calmette-Guerin
strain Glaxo-Evans, corresponding to a multiplicity of infection
of 1 bacillus to 1 monocyte, assuming 4 × 105 monocytes/mL of
peripheral blood [19]. After 6 days, supernatants were removed,
cells were lysed in 10 mL of RNA/DNA Stabilization Reagent
for Blood/Bone Marrow (Roche Applied Science, Basel, Swit-
zerland), and specimens were frozen at −80°C.
Messenger RNA (mRNA) Isolation and Affymetrix GeneChip
Hybridization
mRNA was isolated using the mRNA Isolation Kit for Blood/
Bone Marrow (Roche Applied Science), quantiﬁed using the Ri-
boGreen RNA quantitation method (Life Technologies, Paisley,
United Kingdom), and processed using NuGEN Ovation re-
agents, to enhance sensitivity [20]. For each sample, 500 pg of
mRNA was processed and hybridized to a Human Genome
U133 Plus 2.0 Array GeneChip, as described previously [9].
Microarray Data Analysis
Microarray data ﬁles are deposited in the National Center for
Biotechnology Information Gene Expression Omnibus Data-
base under accession numbers GSE45386 (healthy BCG-vacci-
nated donors) and GSE67589 (patients with tuberculosis). Data
were analyzed using GeneSpring GX 11.5 Software (Agilent
Technologies). Affymetrix CEL ﬁles were processed by the
GC robust multiarray average method and normalized. For
the healthy BCG-vaccinated donor experiment, 47 014 of
54 675 gene entities were analyzed, and for the study of patients
with tuberculosis 44 252 of 54 675 gene entities were analyzed,
after ﬁltering out genes whose expression values never exceeded
the 20th percentile. Log2-transformed data are shown. Two-way
analysis of variance (ANOVA), principal component analysis,
and gene ontology (GO) pie chart generation were conducted
using GeneSpring GX software. Further GO analyses were con-
ducted using the Database for Annotation, Visualization, and
Integrated Discovery (DAVID; available at: http://david.abcc.
ncifcrf.gov/home.jsp [21]). The EASE score refers to a 1-tailed
Fisher exact probability value in the DAVID system. Receiver-
operator characteristic (ROC) curve analyses were conducted
using GraphPad Prismv6.02.
Real-Time Quantitative Reverse-Transcription Polymerase Chain
Reaction (qRT-PCR) Analysis
mRNA was reverse transcribed in duplicate by using Super-
script III (Invitrogen) according to manufacturer’s instructions,
with 5 ng of mRNA per 20-µL reaction. Negative controls were
included without reverse transcriptase, to exclude genomic
DNA contamination. Samples were diluted with 80 µL of
RNAse-free water (Applied Biosystems, Cheshire, United King-
dom), and 5 µL of complementary DNA was used per 20-µL
real-time qRT-PCR reaction. PCR was performed using SYBR-
Green (Applied Biosystems) on an ABI Prism 7000 or 7500 Fast
machine, followed by melting curve analysis: conditions were
95°C for 10 minutes, followed by 40 cycles of 95°C for 15 sec-
onds and 60°C for 60 seconds. Absolute gene expression
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quantiﬁcation was achieved by reference to 10-fold dilutions of
PCR-generated DNA standards. Most primer pairs, purchased
from Sigma-Aldrich, were designed using Primer3 software [22]
as either intron-spanning sequences or as sequences binding
separate exons; primer pairs for HPRT [23] and HuP0 [24]
were obtained from the literature. Primer sequences are
shown in Supplementary Table 1.
RESULTS
Human Transcriptomic Responses to Mycobacteria in Cultures of
Diluted Whole-Blood Specimens
First, we investigated whether incubation of whole blood with
live mycobacteria provides a sensitive platform to analyze global
transcriptomic changes during immune responses. Preliminary
ﬂow cytometry experiments showed both M. tuberculosis and
M. bovis bacillus Calmette-Guerin stimulated various lympho-
cyte populations in diluted whole-blood cultures after 6 days
(data not shown). Diluted whole-blood specimens from 3
BCG-vaccinated donors were, for 6 days, stimulated with
M. bovis bacillus Calmette-Guerin or M. tuberculosis or left
unstimulated, and mRNA was analyzed by microarray. Both
M. tuberculosis and M. bovis bacillus Calmette-Guerin had
strong effects on gene expression, with >8000 genes differen-
tially expressed by ≥2-fold between at least 2 conditions (Fig-
ure 1A). For approximately 2300 genes, M. tuberculosis and
M. bovis bacillus Calmette-Guerin exerted a similar effect: GO
analysis showed that genes involved in a broad range of biolog-
ical processes, including signaling and multicellular processes,
were represented among these regulated genes. Immune system
genes also included a broad range of processes, including devel-
opment, activation, effector process, migration, and immune re-
sponse terms (Figure 1B). In contrast, M. tuberculosis and
M. bovis bacillus Calmette-Guerin exerted different or opposing
effects on approximately 5700 genes: these included a narrower
range of gene ontologies, with overrepresentation of cell compo-
nent biogenesis genes with antigen processing and presentation
dominating the immune system category (Figure 1C). These
may represent important immune evasion strategies.
qRT-PCR assays were performed to ensure that the microar-
ray results could be validated. Initially, reference housekeeping
Figure 1. Mycobacterium tuberculosis and Mycobacterium bovis bacillus Calmette-Guerin can enhance or suppress gene expression in diluted whole-blood cultures. A,
Diluted whole blood from 3 BCG-vaccinated donors was cultured for 6 days alone (control) or in the presence of live M. tuberculosis or M. bovis bacillus Calmette-Guerin.
Messenger RNAwas extracted and pooled for each condition, prior to hybridization to Affymetrix U133 Plus 2.0 microarrays. Data were normalized against the control sample.
The heat map shows 8067 gene entities that were differentially expressed≥2-fold between at least 2 conditions, following Euclidean complete linkage hierarchically clustering.
Gene ontology analysis of the 2293 genes, which were similarly up- or down- regulated by both mycobacteria (B), or the 5774 genes, which showed opposing responses to M.
tuberculosis and M. bovis bacillus Calmette-Guerin (C), are shown for gene ontology categories that were significantly overrepresented (P < 5 × 10−5). All data analysis was
conducted in GeneSpring GX.
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genes were identiﬁed. Expression of 7 potential housekeeping
genes [25–28] was measured in samples generated from diluted
whole-blood specimens obtained from 5 BCG-vaccinated donors
and cultured for 6 days with M. tuberculosis, M. bovis bacillus
Calmette-Guerin, or medium alone. The best 3 housekeeping
genes, showing the highest expression stability across samples,
were HuP0, cyclophilin A, and TBP (Supplementary Figure 1),
determined using the GeNorm application [29].
Next, we measured expression of 2 cytokines interferon γ
(IFN-γ) and interleukin 32 (IL-32) by qRT-PCR in 6 indepen-
dent BCG-vaccinated donors. Upregulation of IFN-γ induced
by both M. bovis bacillus Calmette-Guerin and M. tuberculosis
was similar to that observed in the microarray experiment
(Figure 2A), whereas potent upregulation of IL-32 speciﬁcally
by M. tuberculosis was also replicated (Figure 2B). Finally, ex-
pression of 2 lysosomal enzymes, IFN γ–inducible protein 30
(IFI30) and acid phosphatase 2 (ACP2), upregulated by
M. bovis bacillus Calmette-Guerin but not M. tuberculosis in
the microarray experiment, was conﬁrmed by qRT-PCR (Fig-
ure 2C and 2D). These data showed that differential responses
to M. bovis bacillus Calmette-Guerin and M. tuberculosis were
gene speciﬁc and not due to overall different stimulatory capac-
ity of the mycobacteria. Biological and technical replication
showed that stimulation of diluted whole-blood cultures with
live mycobacteria provided a robust method to measure
human transcriptomic responses. As different mycobacteria
elicited strikingly different responses, subsequent work was
conducted with live M. tuberculosis.
Patients With Tuberculosis Relapse Exhibit Altered Immune Responses
to M. tuberculosis In Vitro
To ﬁnd biomarkers that might predict relapse, 263 HIV-nega-
tive, smear-positive patients with a ﬁrst episode of tuberculosis
were recruited in the Surrogate Marker study in Cape Town as
previously described [4], and blood samples were collected dur-
ing the ﬁrst-episode treatment period. After 6 months of treat-
ment, 191 patients from this cohort were deemed cured.
However, 10 of these patients subsequently experienced re-
lapsed during the 2-year follow-up (hereafter, “the tuberculo-
sis-relapse group”), and their samples were analyzed in this
Figure 2. Validation of diluted whole-blood assay results by real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis. Real-time qRT-PCR
was conducted on samples from 6 BCG-vaccinated donors, independent from the 3 donors used in Figure 1. Results for interferon γ (IFN-γ; A), interleukin 32 (IL-32) (B),
interferon gamma-inducible protein 30 IFI30 (D), and acid phosphatase 2 (ACP2; D) are shown as the number of transcript copies of the gene of interest divided by the geometric
mean number of copies of the 3 housekeeping genes cyclophilin A, HuP0, and TBP, within each sample. Bars show the mean and standard error of the mean. Microarray data
are shown for comparison. *P < .05 and **P < .01, by the Mann–Whitney U test. Abbreviation: CON, control.
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study. From the remaining patients who were successfully cured
and remained disease free for 2 years, 10 were randomly selected
for comparison (hereafter, “the cured group”). Following selec-
tion, the patient groups were compared to ensure there was
overall similarity in age, sex, and clinical characteristics at re-
cruitment, to prevent confounding (Table 1).
To investigate whether patients with tuberculosis relapse dif-
fered in their responses to live M. tuberculosis in cultures of di-
luted whole-blood specimens, samples collected at diagnosis
and after 2 and 4 weeks of tuberculosis treatment were analyzed
by microarray. In 2-way ANOVA, 668 of 44 252 genes were sig-
niﬁcantly differentially expressed between the tuberculosis-re-
lapse and cured groups (Supplementary Tables 2 and 3): this
was substantially higher than 74, the number that would be ex-
pected by chance. When the more stringent Bonferroni multiple
testing correction was applied, 18 genes were signiﬁcantly dif-
ferentially expressed between patients with relapse and those
who were cured (Table 2), including several genes involved in
cell-mediated cytotoxicity, such as perforin, granulysin, and
fas ligand, which were more highly expressed in samples from
patients with relapse. In accordance with previous reports using
ex vivo blood [11, 12], large-scale changes in gene expression
occurring during tuberculosis treatment were evident, irrespec-
tive of treatment outcome. The differences observed were not
due to differential cell counts between the groups, as these
were broadly similar at each time point (Supplementary
Table 4).
Clear differences in transcriptomic proﬁles were observed at
the time of tuberculosis diagnosis between patients with relapse
and those who were cured, with 263 genes differentially ex-
pressed by ≥2-fold (Benjamini–Hochberg corrected P < .05;
Supplementary Table 5). The differential expression pattern
across the ﬁrst 4 weeks of treatment was strikingly consistent
(Figure 3A), indicating that differences were fundamentally
related to the responsiveness of patients to M. tuberculosis. In
ex vivo unstimulated samples, there were no signiﬁcant differ-
ences between the study group in expression of the 668 genes
when a multiple testing correction was applied (data not
shown).
Prediction of Tuberculosis Relapse, Using 668-Gene or 18-Gene
Signatures in M. tuberculosis–Stimulated Samples
We investigated whether tuberculosis outcomes for individual
patients could be predicted on the basis of expression of the
668-gene signature. Hierarchical clustering showed that 8 of
10 patients with relapse grouped together (Figure 3B), implying
common underlying reasons for relapse, but that 2 patients may
have experienced relapsed for different reasons. The patient
clustering was not related to disease severity at diagnosis or to
sputum smear ﬁndings at month 2. Recent studies have shown
that the blood monocyte to lymphocyte (ML) ratio is associated
with the risk of tuberculosis development [30]; however, the ML
ratio was not related to patient clustering in this study (Fig-
ure 3B). The clustering was also unrelated to the degree of
IFN-γmRNA expression induction (data not shown). Principal
component analysis using the 668-gene-signature showed that
the majority of samples segregated depending on whether pa-
tients subsequently experienced relapse or remained cured
(Supplementary Figure 3A) and that samples tended to group
closely by patient (data not shown). Segregation was more evi-
dent when using the 18 highly signiﬁcantly differentially ex-
pressed genes (Figure 3C). Classiﬁcation models were also
more accurate with the 18-gene signature, with an overall pre-
dictive accuracy of 0.84 with a naive Bayes model and of 0.82
with a partial least squares model, as opposed to 0.72 for each
model with the 668-gene signature (Supplementary Figure 3B).
Molecular signatures were derived for each sample by using the
8 genes that were upregulated in cured patients from the 18-
gene signature (Supplementary Figure 3C) and the 10 genes
that were upregulated in the patients who experienced relapse
(Supplementary Figure 3D). ROC curve analysis showed that
both the 8-gene and 10-gene molecular signatures were accurate
at predicting relapse, with AUCs of 0.936 and 0.931, respective-
ly (Figure 3D).
GO Analysis Reveals the Importance of Cytotoxicity in
Relapse Discrimination
GO analysis of the 668-gene signature list showed substantial
overrepresentation of genes involved in biological regulation
and response to stimuli (Figure 4A). There was also signiﬁcant
overrepresentation of genes involved in the immune response
(Figure 4A). To further understand which aspects of the im-
mune response were differentially expressed between patients
with relapse and those who were cured, the DAVID functional
annotation tool was used to interrogate the biological processes
GO terms more deeply. Twenty-three biological processes GO
terms were identiﬁed, with ≥15 gene members and an EASE
Table 1. Characteristics of the Patients Selected for Analysis
Characteristic
Cured Group
(n = 10)
Tuberculosis-Relapse
Group (n = 10)
Age, y, median (range) 31 (19–52) 41 (22–63)
BMI, median (range)a 18.3 (12.3–22.0) 16.7 (14.2–20.4)
Male sex 8/10 8/10
Size of cavities, mm
2–4 5 5
>4 6 4
Radiological extent of disease
Moderate 3 3
Severe 6 7
Sputum smear finding at 2 mo
Positive 4 5
Negative 5 5
Unknown 1 0
a Body mass index (BMI) is calculated as the weight in kilograms divided by the height in
meters squared.
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score <0.05 (Figure 4B). There was striking enrichment of genes
involved in the induction of programmed cell death and apo-
ptosis, with 9 of 23 GO terms related to this phenomenon (Fig-
ure 4B): these GO terms include the extrinsic apoptotic pathway
elicited by cytotoxic immune cells, which were upregulated in
the tuberculosis-relapse group. Genes involved in gene tran-
scription were also signiﬁcantly overrepresented in the 668-
gene signature list (Figure 4B).
Excessive Cytolytic Gene Expression in Patients With Relapse Was Also
Observed by qRT-PCR
To conﬁrm these ﬁndings, qRT-PCR experiments were con-
ducted with mRNA samples from the original 20 patients ana-
lyzed by microarray and from 1 further patient with
tuberculosis relapse who had been deemed to have completed
treatment but subsequently relapsed. A further 17 successfully
cured patients were also analyzed, including those with moder-
ate and severe tuberculosis at diagnosis. The tuberculosis-
relapse and cured patient groups analyzed by qRT-PCR were
similar in terms of age, sex balance, month 2 sputum conver-
sion, and proportion severely diseased at diagnosis (Supple-
mentary Figure 2), whereas there was a higher proportion of
men in these study groups than in the whole patient cohort, re-
ﬂecting the association between male sex and relapse previously
reported in this cohort [4]. mRNA expression of the cytotoxic
effector molecules granulysin (Figure 5A), perforin (not
shown), and fas ligand (Figure 5B) were signiﬁcantly higher
in tuberculosis-relapse patients than in cured patients, as was
expression of Rab27A, which regulates secretion of cytotoxic
granules (Figure 5C). In contrast, the expression of pragmin
was higher in cured patients (Figure 5D), in accordance with
the microarray data.
DISCUSSION
We have identiﬁed transcriptomic signatures in M. tuberculo-
sis–stimulated whole-blood cultures that discriminated patients
with tuberculosis who subsequently experienced relapse from
those who remained cured for 2 years. The ability to predict
which patients with tuberculosis are at risk of relapse after treat-
ment completion would facilitate clinical management and en-
hance efﬁcacy testing of new tuberculosis drugs, especially in
early phase clinical trials. The majority of patients in this
study (8 of 10) were correctly allocated to the tuberculosis-
Table 2. Genes Most Significantly Differentially Expressed Between the Tuberculosis-Relapse and Cured Groups After Stimulation With Mycobacterium
tuberculosis In Vitro
Affymetrix Probe
ID Gene Symbol Gene Name Function
Patient Group With Higher
Gene Expression P Values
239754_at C17orf76? C17orf76/SNORD49A/B/SNORD65 Unknown—ambiguous probe set Relapse .002518
1552623_at HSH2D Hematopoietic SH2 domain
containing
Adaptor protein, negative regulator of
T-cell activation
Relapse .011216
37145_at GNLY Granulysin Cytotoxicity Relapse .011639
212805_at PRUNE2 Prune homolog 2 Regulation of differentiation and survival
of tumour cells
Relapse .018670
209765_at ADAM19 Metallopeptidase domain 19 Cell-cell and cell-matrix interaction and
DC marker
Relapse .020138
209515_s_at RAB27A RAB27A Regulation of secretion including
cytotoxic granules
Relapse .030276
1553681_a_at PRF1 Perforin 1 Cytotoxicity Relapse .042316
226863_at FAM110C Family with sequence similarity
110, member C
Cell cycle regulation, localized to
centrosomes
Relapse .043196
203588_s_at TFDP2 Transcription factor Dp-2 Dimerization with E2F for activation of
cell cycle genes
Relapse .045783
211333_s_at FASLG Fas ligand Cytotoxicity Relapse .049411
236858_s_at RUNX2 Runt-related transcription factor 2 Osteoblastic differentiation and TGF-β
signaling
Cured .000612
1569040_s_at ANKRD36BP2 Ankyrin repeat domain 36B
pseudogene 2
Pseudogene (related to structural
protein)
Cured .001928
336_at TBXA2R Thromboxane A2 receptor Platelet aggregation and haemostasis Cured .010481
227805_at METAP1D Methionyl amino-peptidase type 1D Proteolysis Cured .015718
235085_at SGK223 Pragmin Regulator of Src family kinases, signal
transduction
Cured .028989
206873_at CA6 Carbonic Anhydrase VI Salivary protein Cured .029041
232844_at IFT140 Intraflagellar transport 140 homolog Development and function of cilia Cured .031645
215946_x_at IGLL3P Immunoglobulin lambda-like
polypeptide 3
Pseudogene (related to immunoglobulin
λ)
Cured .048079
Gene entities that were >2-fold differentially expressed between any pair of conditions and had a P value of <.05 by 2-way analysis of variance with the Bonferroni familywise error rate
correction multiple testing correction are shown.
Abbreviation: TGF-β, transforming growth factor β.
490 • JID 2016:213 (1 February) • Cliff et al
 by guest on February 22, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
relapse or cured groups, based on expression of a 668-gene sig-
nature. Intriguingly, there was clear-cut discrimination of the
majority of patients by principal component analysis: the
distinction was present at the time of tuberculosis diagnosis, im-
plying that these patients had inherently different immune re-
sponses to live M. tuberculosis, rather than a differential
Figure 3. Blood gene expression patterns are consistent over 4 weeks of tuberculosis treatment and can be used to classify patient outcome. A, Expression patterns of genes
differentially expressed between tuberculosis-relapse and cured groups in Mycobacterium tuberculosis–stimulated diluted whole-blood cultures over the first 4 weeks of tu-
berculosis treatment. The normalized hybridization intensity of expression of 381 genes found to be ≥2-fold differentially expressed (P < .05, with Benjamini–Hochberg false-
discovery rate correction) at at least one time point is shown for the mean of each patient group at the indicated time points. Genes have been hierarchically clustered using a
Euclidean algorithm in GeneSpring GX. B, Hierarchical clustering was performed, using a Euclidean similarity measure and centroid linkage rule, for both patients and genes,
using the 309 genes that were on average ≥2-fold differentially expressed between tuberculosis-relapse and cured groups in diluted whole-blood samples collected after 4
weeks of treatment, following stimulation in vitro with live M. tuberculosis. The table shows the treatment outcome (C = cure and R = relapse), the disease severity at diagnosis
(M = moderate or S = severe, based on chest radiography findings), the 2-month sputum smear result, and the ratio of lymphocytes to monocytes in blood at the time of
tuberculosis diagnosis for each patient. C, Principal component analysis was performed for samples from the 10 patients with relapse and the 10 cured patients at the 3
time points, using the 18 genes that were highly significantly ≥2-fold differentially expressed, using the Bonferroni familywise error rate correction (Supplementary Table 4). D,
Molecular signatures were derived for each sample by summing the normalized log2-transformed hybridization intensity data for the 8 genes that were upregulated in the cured
group and the 10 genes that were upregulated in the tuberculosis-relapse group, according to analysis of variance (Table 2). Receiver operating characteristic curve analyses
were conducted to determine the accuracy of the molecular signatures, to determine treatment outcome. In the treatment-relapse group, 9 had data at diagnosis, 8 had data
from week 2, and 10 had data from week 4. In the cured group, 10 had data at all time points. Abbreviation: AUC, area under the curve.
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Figure 4. Gene ontology (GO) analysis of 668-gene entities differentially expressed between the cured group and the tuberculosis-relapse group. A, GO analysis of the 668
gene entity list from the analysis of variance (Supplementary Table 2) was conducted in GeneSpring GX to grossly allocate function to the gene list. Biological processes are
shown where they are overrepresented within the 668 gene entity list (P < .1). B, The same gene list was inputted into the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) functional annotation tool. A total of 506 entities were mapped to unique known genes in the DAVID database, and 23 biological process
GO terms, containing ≥15 entities and with an EASE score of <0.05, were identified within the gene entity list. GO terms are shown clustered by function. Fold–enrichment
values, showing overrepresentation of the term within the 506 gene list, are plotted as bars on the top axis; values calculated on the basis of 1 – [EASE score] are plotted as
dots on the bottom axis.
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response to treatment. The misclassiﬁed patients exhibited
more-complex mixed signatures. The likelihood of a relapsed,
cured, or mixed phenotype in this study was not related to dis-
ease extent at diagnosis or sputum conversion at 2 months,
highlighting that patients can experience relapse for different
reasons. In an earlier study [11], subjects who had previously
experienced recurrent tuberculosis had different blood tran-
scriptomic proﬁles, compared with those who remained cured
after 1 tuberculosis episode, even though blood specimens
were collected from subjects while they were healthy and disease
free, substantiating a role of inherent difference.
The relapse-risk gene signature included an exacerbated cy-
totoxicity response to M. tuberculosis in vitro, accompanied by
higher expression of cell cycle genes indicative of excessive lym-
phocyte proliferation. Patients with tuberculosis develop pe-
ripheral CD8+ T cell cytotoxic T-lymphocyte (CTL) responses
to a variety of antigens, such as Ag85A and ESAT-6 [31, 32], but
the magnitude is reduced in patients with pulmonary tubercu-
losis, compared with latently infected healthy people [33, 34],
possibly because of enhanced cell sequestration in the lungs
of patients with tuberculosis or because of reduced cytolytic ca-
pacity of antigen-speciﬁc CTLs via regulatory mechanisms.
Cell-mediated killing of host cells does not necessarily lead to
mycobacterial killing and may drive recruitment of neutrophils.
In mice, deletion of the regulatory protein PD1 leads to reduced
mycobacterial control and more-rapid death [35], owing to ex-
cessive lung inﬂammation [36]. Here, conceivably, the inherent-
ly excessive cytotoxic inﬂammatory response in the patients
with relapse led to exacerbated lung immunopathology, and
the inﬂammatory response to remaining bacilli resumed once
drug treatment ceased, causing further disease. It is possible
that nonsterile cure can be achieved in most patients with tuber-
culosis, via development of an appropriately regulated effective
T-cell response.
The 668-gene signature contained genes both up and down
regulated in the relapse group compared to the cured group,
with 356 genes more highly expressed in the cured group.
Eight of the genes within the 18-gene highly signiﬁcantly differ-
entially expressed gene signature were more highly expressed in
the cured group. These included Pragmin, which is involved in
Figure 5. Validation of microarray results by real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The expression of granulysin (A), fas ligand (B),
rab27A (C), perforin (D), and pragmin (E ) were measured by qRT-PCR in diluted whole-blood cultures stimulated for 6 days with live Mycobacterium tuberculosis H37Rv at the
time of tuberculosis diagnosis and after 4 weeks of treatment. Data are for 11 patients in the tuberculosis-relapse group (2 with moderate and 9 with severe disease at the time
of tuberculosis diagnosis) and for 27 patients in the cured group (6 with moderate and 21 with severe disease at the time of tuberculosis diagnosis). Data are as the number of
copies of the gene of interest normalized against the geometric mean number of copies of HuP0, HPRT, and TBP. The box plots show the 25–75th percentile for the data set,
with the line denoting the median, the whiskers showing the 5th–95th percentiles, and the dots showing the outliers. *P < .05 and **P < .01, by the Mann–Whitney U test.
Abbreviation: mRNA, messenger RNA.
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facilitating immune cell signaling by sequestering the negative
regulator C-terminal Src kinase (Csk) in the cytoplasm [37];
downregulation in the tuberculosis-relapse group might damp-
en immune cell activation. The transcription factor RUNX2 was
also downregulated in patients with relapse, potentially inhibit-
ing PI3K/AKT cell signaling [38].
The inherently different immune response to M. tuberculosis
in patients with relapse in this study was present at the time of
tuberculosis diagnosis and during the ﬁrst 4 weeks of treatment.
Measuring responses later in treatment might identify patients
with tuberculosis relapse for further reasons. Although the 2-
month sputum conversion rate is often used as an indicator
of tuberculosis drug efﬁcacy, data regarding the association be-
tween smear/culture conversion and successful tuberculosis
treatment outcome are inconsistent [39]. In 2 recent noninfer-
iority clinical trials of gatiﬂoxacin [40] or moxiﬂoxacin [41] ef-
ﬁcacy, aimed at shortening the duration of tuberculosis
treatment, substantially higher recurrence and relapse rates oc-
curred in experimental study arms despite more-rapid sputum
conversion rates, compared with arms that received standard
treatment. These trials demonstrate that some patients remain
at risk of relapse after early effective bacterial killing, presum-
ably owing to mycobacterial persistence in the absence of estab-
lishment of an effective immune response.
A clinically useful algorithm for predicting tuberculosis re-
lapse or durable cure will likely include a combination of host
gene expression, serum markers and microbiological readout.
In a parallel study (Ronacher K, Chegou NN, Djoba Siawaya
JF, et al, unpublished data), serum tumor necrosis factor β
and soluble interleukin 6 receptor levels at the time of diagnosis
correlated with the risk of tuberculosis relapse; these cytokines
are markers of an inﬂammatory response. The next stage in the
development of biomarkers to predict tuberculosis relapse will
be testing transcriptomic signatures in much larger study
cohorts. The study presented here was conducted using one
of the largest cohorts currently available of patients with tuber-
culosis relapse, but validation in a large, independent, geo-
graphically distinct cohort would prove the ability of this
transcriptomic signature for predicting tuberculosis relapse. Fu-
ture relapse-prediction biomarker studies could be combined
with existing tuberculosis drug and vaccine trials, to facilitate
sample collection in the context of high-quality clinical and mi-
crobiological data collection from large study cohorts, including
HIV-positive individuals. Although ex vivo blood samples are
readily collected in ﬁeld trials, it is noteworthy that the 668-
gene signature that discriminated patient groups in the current
study was not observed in matching ex vivo samples, and in
vitro antigen-speciﬁc stimulation may add further discrimina-
tory power to a combination biosignature. It is possible that
the different patient groups responded with different kinetics
following in vitro stimulation, and this could also be addressed
in future studies. It may be possible to facilitate wider scale roll-
out by adapting methodology using other mycobacterial prep-
arations or antigens, such as QuantiFERON-TB Gold tube cell
pellets, which might allow collection of samples after overnight
culture. Measurement of protein concentrations in future stud-
ies would also provide functional rationale for inclusion in pre-
dictive biosignatures.
A composite biosignature trial end point, which accurately
discriminates durable cure from risk of tuberculosis relapse,
would allow more compounds and regimens to be tested
more rapidly and cost-effectively. Recently, bedaquiline was
conditionally approved by the Food and Drug Administration
for multidrug-resistant (MDR) tuberculosis treatment; approval
was based on 2-month sputum conversion data [42] with no
randomized, controlled efﬁcacy studies, as the need for new
MDR tuberculosis drug need is so acute. However, there is cur-
rently no evidence of improved treatment outcome, and the use
of inappropriate surrogate markers of cure could be very dam-
aging in tuberculosis drug and regimen development [43]. The
cytotoxic cell gene signature described here could be developed
into one arm of a composite treatment outcome biosignature,
which could be used for patient stratiﬁcation in drugs trials.
The discrimination of patients with relapse from those who
achieved cure also indicates avenues of research for the develop-
ment of host-directed therapy.
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